These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22421702)

  • 1. Amantadine-induced myoclonus in a patient with progressive supranuclear palsy.
    Yarnall AJ; Burn DJ
    Age Ageing; 2012 Sep; 41(5):695-6. PubMed ID: 22421702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of progressive supranuclear palsy].
    Finali G; Piccinin GL; Piccirilli M; Stefano E
    Clin Ter; 1989 Jun; 129(5):339-51. PubMed ID: 2569956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of progressive supranuclear palsy and corticobasal degeneration.
    Lang AE
    Mov Disord; 2005 Aug; 20 Suppl 12():S83-91. PubMed ID: 16092096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological hypersexuality induced by dopamine replacement therapy in a patient with progressive supranuclear palsy.
    Kim YY; Park HY; Kim JM; Kim KW
    J Neuropsychiatry Clin Neurosci; 2008; 20(4):496-7. PubMed ID: 19196941
    [No Abstract]   [Full Text] [Related]  

  • 5. A Review of Treatment Options for Progressive Supranuclear Palsy.
    Stamelou M; Höglinger G
    CNS Drugs; 2016 Jul; 30(7):629-36. PubMed ID: 27222018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Edemas and myocloni concerning a patient with Parkinson's disease treated by amantadine (author's transl)].
    Chevalier JF; Renier E; Brion S
    Encephale; 1980; 6(4):381-4. PubMed ID: 7439114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy.
    O'Sullivan SS; Djamshidian A; Ahmed Z; Evans AH; Lawrence AD; Holton JL; Revesz T; Lees AJ
    Mov Disord; 2010 Apr; 25(5):638-42. PubMed ID: 20213825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases.
    Birdi S; Rajput AH; Fenton M; Donat JR; Rozdilsky B; Robinson C; Macaulay R; George D
    Mov Disord; 2002 Nov; 17(6):1255-64. PubMed ID: 12465065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Descriptive study of a serie of patients affected by progressive supranuclear palsy].
    Villanueva-Haba VE; Garcés M; de Vera A; Valero C; Burguera JA
    Rev Neurol; 2001 Jun 1-15; 32(11):1027-30. PubMed ID: 11562823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].
    Ceballos-Baumann AO
    MMW Fortschr Med; 2002 May; Suppl 2():37-43. PubMed ID: 12070848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excessive dopamine neuron loss in progressive supranuclear palsy.
    Murphy KE; Karaconji T; Hardman CD; Halliday GM
    Mov Disord; 2008 Mar; 23(4):607-10. PubMed ID: 18163454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dopaminergic drug-induced jaw-opening dystonia in a patient with progressive supranuclear palsy].
    Tano O; Kaneko K; Kikuchi A; Hasegawa T; Takeda A; Aoki M
    Rinsho Shinkeigaku; 2013; 53(4):308-11. PubMed ID: 23603547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease and look-alikes.
    Khadilkar SV
    J Assoc Physicians India; 2010 Feb; 58():75. PubMed ID: 20653146
    [No Abstract]   [Full Text] [Related]  

  • 15. Amantadine may reverse punding in Parkinson's disease--observation in a patient.
    Kashihara K; Imamura T
    Mov Disord; 2008 Jan; 23(1):129-30. PubMed ID: 17960816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward future therapies in progressive supranuclear palsy.
    Burn DJ; Warren NM
    Mov Disord; 2005 Aug; 20 Suppl 12():S92-8. PubMed ID: 16092097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An autopsy case of progressive supranuclear palsy with olivary hypertrophy].
    Takeuchi M; Sasaki S; Ito A; Osawa M; Kobayashi I; Maruyama S
    No To Shinkei; 1991 Sep; 43(9):863-7. PubMed ID: 1742094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subthalamic stimulation improves levodopa responsive symptoms in a case of progressive supranuclear palsy.
    Bergmann KJ; Salak VL
    Parkinsonism Relat Disord; 2008; 14(4):348-52. PubMed ID: 17825599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive supranuclear palsy.
    Pourfar M; Vonsattel JP
    Sci Aging Knowledge Environ; 2004 Jul; 2004(30):dn1. PubMed ID: 15282366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Likely amantadine-induced livedo reticularis in a child.
    Barrera F; Browning JC
    Pediatr Dermatol; 2012; 29(3):329-30. PubMed ID: 21995348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.